Revance Therapeutics announced that the U.S. FDA has accepted for review a supplemental Biologics License Application for DAXXIFY for injection for the treatment of cervical dystonia in adults, a chronic and debilitating neurologic condition affecting the muscles of the neck. Revance was provided a Prescription Drug User Fee Act date of August 19, 2023.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RVNC: